Qurient Files International Patent for Dual Payload ADC Platform

Expanding IP from QP101 as an Individual Candidate to a Platform Technology

Establishing the Foundation for Application to Various Antibodies and Targets…Pursuing Global Business Collaboration

Qurient announced on the 28th that it has filed an international patent (PCT) application for its dual payload antibody-drug conjugate (ADC) platform technology.

Qurient company logo image. Qurient

This patent extends the scope of the platform technology based on the HER2-targeting dual payload ADC 'QP101' patent filed last year. The dual payload design applied in QP101 now has an expanded scope of rights so that it can be used for various target antibodies.

Through this application, Qurient has secured a foundation of intellectual property rights that enables the application of its dual payload ADC technology to various antibodies and targets, while maintaining the individual patent rights for QP101. Based on this, the company plans to pursue collaborations such as joint development and platform technology transfer with global pharmaceutical and biotech companies.

Nam Kiyoun, CEO of Qurient, said, “We have laid the groundwork to expand the dual payload ADC technology secured during the development of QP101 into a global platform business,” adding, “We will expand our business foundation by collaborating with global companies so that the technology can be applied to a wide range of target antibodies.”

This content was produced with the assistance of AI translation services.